Mechanism of Gynecomastia and Erectile Dysfunction from Aldosterone Antagonists
Spironolactone causes gynecomastia and erectile dysfunction through its nonselective anti-androgenic effects: it directly blocks androgen receptors at target tissues, increases the metabolic clearance rate of testosterone, enhances peripheral conversion of testosterone to estradiol, and may impair testicular steroidogenesis—all of which disrupt the testosterone-to-estradiol ratio. 1
Primary Mechanisms
1. Direct Anti-Androgenic Action at Target Tissues
Spironolactone is a nonselective mineralocorticoid receptor antagonist that also binds to androgen receptors in peripheral tissues, directly blocking testosterone's effects 2. This competitive inhibition at the receptor level prevents normal androgenic signaling in breast tissue, reproductive organs, and other androgen-sensitive tissues.
2. Altered Testosterone-to-Estradiol Ratio
The drug fundamentally disrupts sex hormone balance through multiple pathways 3:
Increased testosterone clearance: Spironolactone significantly increases the metabolic clearance rate of testosterone (p < 0.02), resulting in lower circulating testosterone levels (2.7 ± 0.5 ng/ml vs 4.4 ± 0.4 ng/ml in controls) 3
Enhanced aromatization: The peripheral conversion rate of testosterone into estradiol increases significantly (p < 0.001), leading to elevated estradiol levels (30 ± 4 pg/ml vs 13 ± 2 pg/ml in controls) 3
Net effect: This creates a feminizing hormonal environment with relatively more estrogen and less testosterone
3. Impaired Testicular Steroidogenesis
Acute administration can decrease plasma testosterone levels without changes in gonadotropins, suggesting direct inhibition of testicular testosterone production 2, 4.
Clinical Manifestations
Gynecomastia Characteristics
- Dose-dependent: Occurs in 10% of males at 25 mg/day, but up to 52% at doses ≥150 mg/day 1
- Timing: May appear as early as 1-2 months but more commonly after ≥6 months of treatment 5
- Usually reversible: Particularly if caught early and dose reduced or drug discontinued 5
Sexual Dysfunction
Includes decreased libido, impotence, and erectile dysfunction—all consequences of the anti-androgenic effects and altered hormone ratios 1, 4.
Key Distinction: Eplerenone Does NOT Cause These Effects
Eplerenone is a selective mineralocorticoid receptor antagonist that lacks the anti-androgenic properties of spironolactone 1. It does not bind to androgen receptors and therefore does not cause gynecomastia or sexual dysfunction 6. This selectivity makes eplerenone the preferred choice in men when available, despite requiring 2-3 times higher doses for equivalent blood pressure control 1.
Clinical Pitfalls to Avoid
- Don't assume bilateral presentation: While typically bilateral, spironolactone can cause unilateral gynecomastia 7
- Don't ignore early symptoms: Dose reduction to ≤50 mg/day may resolve gynecomastia in younger males if caught early, before progression to advanced size 5
- Don't overlook drug interactions: The anti-androgenic effects are intrinsic to spironolactone's structure, not due to drug interactions
- Don't confuse with aromatase stimulation: Despite increased estradiol, spironolactone does NOT directly stimulate aromatase enzyme activity 8—the increased conversion occurs through enhanced substrate availability and clearance mechanisms
Management Algorithm
When gynecomastia or erectile dysfunction develops on spironolactone:
- First-line: Reduce dose to ≤50 mg/day (especially in younger males) 5
- Second-line: Switch to eplerenone (if available) or amiloride 5, 1
- Expected resolution: Gynecomastia typically resolves completely after discontinuation if not already advanced 5, 9
The mechanism is fundamentally different from prolactin-mediated gynecomastia (as seen with antipsychotics) or pure estrogen excess—it represents a multifaceted disruption of androgen physiology at production, metabolism, and receptor levels 4.